NEW YORK, Jan. 17 (GenomeWeb News) - Ambit Biosciences will profile additional compounds for Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer using its kinase and screening technologies, the San Diego-based company said today.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.
